KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Return on Capital Employed (2016 - 2026)

Biogen has reported Return on Capital Employed over the past 18 years, most recently at 3.07% for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 24.0% year-over-year to 3.07%; the TTM value through Mar 2026 reached 3.07%, down 24.0%, while the annual FY2025 figure was 3.34%, 149.0% down from the prior year.
  • Return on Capital Employed for Q1 2026 was 3.07% at Biogen, up from 3.26% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 14.37% in Q2 2022 and troughed at 3.26% in Q4 2025.
  • A 5-year average of 2.43% and a median of 2.17% in 2023 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: soared 406bps in 2022 and later tumbled -1602bps in 2023.
  • Year by year, Return on Capital Employed stood at 12.77% in 2022, then plummeted by -125bps to 3.25% in 2023, then surged by 45bps to 1.79% in 2024, then tumbled by -83bps to 3.26% in 2025, then rose by 6bps to 3.07% in 2026.
  • Business Quant data shows Return on Capital Employed for BIIB at 3.07% in Q1 2026, 3.26% in Q4 2025, and 2.31% in Q3 2025.